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ABSTRACT Interferon-stimulated gene products (ISGs) play a crucial role in early
infection control. The ISG zinc finger CCCH-type antiviral protein 1 (ZAP/ZC3HAV1)
antagonizes several RNA viruses by binding to CG-rich RNA sequences, whereas its
effect on DNA viruses is less well understood. Here, we decipher the role of ZAP in
the context of human cytomegalovirus (HCMV) infection, a b-herpesvirus that is associ-
ated with high morbidity in immunosuppressed individuals and newborns. We show
that expression of the two major isoforms of ZAP, ZAP-S and ZAP-L, is induced during
HCMV infection and that both negatively affect HCMV replication. Transcriptome and
proteome analyses demonstrated that the expression of ZAP results in reduced viral
mRNA and protein levels and decelerates the progression of HCMV infection. Metabolic
RNA labeling combined with high-throughput sequencing (SLAM-seq) revealed that
most of the gene expression changes late in infection result from the general
attenuation of HCMV. Furthermore, at early stages of infection, ZAP restricts HCMV
by destabilizing a distinct subset of viral mRNAs, particularly those from the previ-
ously uncharacterized UL4-UL6 HCMV gene locus. Through enhanced cross-linking
immunoprecipitation and sequencing analysis (eCLIP-seq), we identified the tran-
scripts expressed from this HCMV locus as the direct targets of ZAP. Moreover, our
data show that ZAP preferentially recognizes not only CG, but also other cytosine-
rich sequences, thereby expanding its target specificity. In summary, this report is
the first to reveal direct targets of ZAP during HCMV infection, which strongly indi-
cates that transcripts from the UL4-UL6 locus may play an important role for HCMV
replication.
IMPORTANCE Viral infections have a large impact on society, leading to major human
and economic losses and even global instability. So far, many viral infections, includ-
ing human cytomegalovirus (HCMV) infection, are treated with a small repertoire of
drugs, often accompanied by the occurrence of resistant mutants. There is no li-
censed HCMV vaccine in sight to protect those most at risk, particularly immuno-
compromised individuals or pregnant women who might otherwise transmit the vi-
rus to the fetus. Thus, the identification of novel intervention strategies is urgently
required. In this study, we show that ZAP decelerates the viral gene expression cas-
cade, presumably by selectively handpicking a distinct set of viral transcripts for
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degradation. Our study illustrates the potent role of ZAP as an HCMV restriction fac-
tor and sheds light on a possible role for UL4 and/or UL5 early during infection, pav-
ing a new avenue for the exploration of potential targets for novel therapies.
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Viral infections pose a major global health burden as the cause of a range of debili-tating human diseases with the potential to paralyze countries. Herpesviruses are
large, structurally complex DNA viruses belonging to the Herpesviridae. Within this fam-
ily, a number of viruses are responsible for a variety of diseases in humans ranging
from cold sores and pneumonia to cancer. The common peculiarity of herpesviruses
lies in their ability to establish latency, which presents a particular challenge due to
severe complications resulting from virus reactivation. Human cytomegalovirus
(HCMV), part of the Betaherpesvirinae subfamily, is one of the nine human herpesvi-
ruses described to date. HCMV displays a coding capacity that exceeds that of most
other Herpesviridae, having the largest genome among all known human viruses and
the capacity to encode more than 200 proteins. Primary HCMV infection generally
causes mild symptoms in immunocompetent individuals (1). However, immunosup-
pressed individuals, such as AIDS patients or transplant recipients, are vulnerable to
HCMV-related disease (2, 3). In addition, HCMV is the leading cause of congenital viral
infection worldwide and can result in serious long-term sequelae in newborns, such as
hearing loss, vision abnormalities, microcephaly, or developmental delays (4).
The host innate immune system, as the first line of defense, is equipped with
germ line-encoded pattern recognition receptors (PRRs), a group of sensors that
detect the presence of pathogens by recognizing pathogen-associated molecular
patterns (PAMPs). The detection of PAMPs induces downstream signaling culminat-
ing in the activation of several transcription factors, including interferon regulatory
factors (IRF) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-
κB), leading to the induction of genes encoding type I interferons (IFNs), proinflam-
matory cytokines, and noncanonical interferon-stimulated genes (ISGs) (5). Upon
binding type I IFNs, the interferon-a/b receptor (IFNAR) is activated, and its signaling
results in nuclear translocation of STAT1 and STAT2 transcription factors and induc-
tion of canonical ISGs (reviewed in reference 6). ISGs are essential antiviral effectors
and constitute a group of cellular factors ranging from PRR (e.g., IFI16, cGAS, or RIG-I)
or transcription factors to proapoptotic proteins or proteins involved in the regula-
tion of the immune response (7).
The zinc finger CCCH-type antiviral protein 1, also known as ZAP, ZC3HAV1, or
PARP13, belongs to the subset of noncanonical ISGs whose expression can be induced
via IRF3 directly as well as canonically by IFNAR signaling (5). Four isoforms of ZAP that
originate from alternative splicing of the ZC3HAV1 gene have been reported thus far
(8), with the long (ZAP-L) and the short (ZAP-S) isoforms being the most prominent
ones. While approximately the first 700 amino acids are shared by ZAP-L and ZAP-S,
ZAP-L has an extended C terminus of around 200 amino acids containing a catalytically
inactive PARP-like domain (9) and a functional CaaX prenylation motif (10). The farnesyl
modification on the cysteine residues of the CaaX motif increases the hydrophobicity
of ZAP-L, targeting this isoform to endolysosomal membranes (10). Both ZAP isoforms
are equipped with an N-terminal zinc finger domain (containing four CCCH-type zinc
finger motifs), a TiPARP homology domain (TPH), which is well conserved among ZAP
paralogs and contains a fifth zinc finger motif, and a WWE domain, predicted to medi-
ate specific protein-protein interactions (11, 12).
ZAP exhibits broad antiviral activity against a variety of RNA viruses by binding RNA
and mediating its degradation (13–16). The antiviral activity of ZAP was demonstrated
against alphaviruses (17), filoviruses (18), retroviruses (16, 19), and flaviviruses (20).
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However, ZAP fails to inhibit a diverse range of other RNA viruses, including vesicular
stomatitis virus (VSV), poliovirus (17), influenza A virus (21, 22), and enterovirus A71
(23). The involvement of ZAP in the defense against DNA viruses has not been
explored to the same extent as for RNA viruses. For instance, ZAP restricts hepatitis B
virus by downregulating viral pregenomic RNA (24). For herpesviruses, while ectopic
expression of ZAP failed to inhibit growth of the a-herpesvirus herpes simplex virus 1
(HSV-1) (17), ZAP could restrict HCMV by an unknown mechanism (25). Interestingly, a
luciferase-based reporter assay identified the HSV-1 UL41 protein, known for its ability
to mediate degradation of several mRNAs, as a ZAP antagonist that degrades ZAP
mRNA, which may explain why ZAP cannot restrict HSV-1 (17, 26). Modified vaccinia vi-
rus Ankara (MVA) was recently shown to be restricted by ZAP, and while the knockout
of ZAP had no discernible effect on viral DNA, individual mRNA, or protein species, an
interference of ZAP with a late step in the assembly of infectious MVA virions was sug-
gested (27).
To date, the molecular details of how ZAP recognizes RNA have not been clearly
defined. Early publications suggest an RNA structure-dependent recognition, based on
the RNA tertiary structure, but already advocating the importance of the sequence-spe-
cific interaction between ZAP and its target RNA (28). The formation of tertiary struc-
tures raises the possibility of multiple binding sites. Subsequent studies support the
recognition of CG-rich dinucleotide regions (19). Indeed, a recent study revealed on a
structural level that ZAP binds to CG-rich RNA with high affinity through its basic sec-
ond zinc finger, which contains a pocket capable of accommodating CG-dinucleotide
bases (29). However, another possibility is the binding of ZAP to AU-dinucleotides.
Although one study reported that ZAP does not recognize any of the three types of
AU-rich elements (AREs) and concluded that ZAP may modulate stability of non-ARE-
containing mRNAs (14), recent publications described ZAP target specificity for
sequences enriched for AU-rich dinucleotides (30, 31). Taken together, while there are
solid data indicating ZAP recognition of CG-dinucleotide-containing RNA, it is feasible
that the presence of several other zinc finger motifs in the ZAP protein broadens its
target specificity. How these target specificities are regulated and the mechanism of
how ZAP-bound RNA is degraded warrant further investigation.
Here, we report that the expression of the ZAP-S and ZAP-L isoforms is induced
upon infection and that both act as restriction factors for HCMV in human primary
fibroblasts (HFF-1). Further, a combination of transcriptomic and proteomic experi-
ments demonstrates that ZAP restricts the progression of HCMV gene expression, con-
sequently affecting viral protein levels. Enhanced cross-linking and immunoprecipita-
tion (eCLIP) revealed that ZAP preferentially cross-links to cytosine-rich regions devoid
of adenosines, rather than recognizing specific motifs. In combination with metabolic
RNA labeling (SLAM-sequencing) we show that ZAP negatively regulates the stability
of the viral transcripts UL4 and UL5 by direct interaction. Together, we provide evi-
dence that ZAP is an important cellular factor that restricts HCMV early during infection
in a distinct manner, by specifically targeting transcripts that originate from the UL4-
UL6 locus expressed with immediate-early to early kinetics.
RESULTS
Expression of ZAP is induced upon HCMV infection. A previous proteomics study
showed that HCMV infection of human fibroblasts (HFF-1) leads to the upregulation of
a specific set of host proteins in the first 24 h, including some ISGs. One of these ISGs
was the antiviral protein ZAP (32). The two major isoforms of ZAP, the short (ZAP-S)
and the long (ZAP-L), are only differentiated by the inclusion of the C-terminal PARP-
like domain in ZAP-L (Fig. 1A). To analyze which of the two major isoforms of ZAP is
induced upon HCMV infection, HFF-1 cells were infected with HCMV or, as a control,
stimulated with recombinant IFN-b , and expression of ZAP was analyzed by immuno-
blotting. Our results show that ZAP-L was expressed in uninfected HFF-1 cells, and its
expression was only marginally increased upon HCMV infection or IFN-b 24 h
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poststimulation (Fig. 1B). In contrast, ZAP-S was barely expressed in untreated cells,
but its expression was strongly induced by HCMV infection and IFN-b treatment
(Fig. 1B). These results show that ZAP-S is a prototypical ISG, which is strongly induced
upon HCMV infection, whereas ZAP-L is already expressed prior to, and only slightly
induced with, infection.
To investigate whether ZAP can shape the course of HCMV infection, we generated
three individual ZAP-deficient HFF-1 cell lines by Cas9-mediated gene editing. Each
cell line was generated using a different guide RNA, all targeting the first exon of
Zc3hav1, and thereby affecting both ZAP-L and ZAP-S expression (Fig. 1C). To verify
the efficacy of genome editing, we infected the knockout (KO) cell lines with HCMV
and analyzed ZAP expression at 24, 48, and 72 h postinfection (hpi). Protein levels of
both ZAP-L and ZAP-S were strongly reduced in all three knockout cell lines (g1, g2,
g3), confirming successful genome editing (Fig. 1D). As a control, we also generated a
cell line with a nontargeting guide RNA. Expression of ZAP followed the same kinetics
FIG 1 Expression kinetics of ZAP-S and ZAP-L in HCMV-infected fibroblasts. (A) Schematic representation of the
protein domains of the two main isoforms of ZAP, the long isoform, ZAP-L, and the short isoform, ZAP-S. Both
isoforms share four CCCH-type zinc finger motifs in the N-terminal domain, as well as a TPH domain containing a fifth
zinc finger motif, and a WWE domain, while the C-terminal PARP-like domain is only present in ZAP-L. TPH, TiPARP
homology domain; PARP, poly(ADP-ribose)-polymerase. (B) Primary human fibroblasts (HFF-1) were either mock-
treated, infected by centrifugal enhancement with HCMV (MOI 0.1), or stimulated by addition of recombinant IFN-b
(20 ng/ml), and expression of ZAP and actin was analyzed 24 h later by immunoblotting with a ZAP- or actin-specific
antibody. (C) Three independent ZAP KO cell lines were generated by Cas9-mediated gene editing using three
different gRNAs (g1, g2, and g3) that target the first exon of the zc3hav1 gene. (D to F) Wild-type HFF-1 and the three
ZAP KO (D) or control (E and F) cell lines were mock-treated or infected by centrifugal enhancement with HCMV (MOI
0.1) for the indicated time points, and cell lysates were subjected to immunoblotting with specific antibodies against
ZAP and actin. Quantifications of ZAP-L (in green) or ZAP-S (in blue) band intensities normalized to actin are
represented in line graphs. hpi, hours postinfection.
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in both wild-type (WT) and control HFF-1 cells, demonstrating that stable expression of
Cas9 did not affect ZAP expression kinetics (Fig. 1E). To pinpoint when ZAP-S expres-
sion begins to increase after HCMV infection, we monitored its protein levels in WT
and control cells at earlier time points (2 to 10 hpi). ZAP-S expression levels started to
be detectable between 6 and 8 h post-HCMV infection and steadily increased over
time (Fig. 1F).
Taken together, these results show that HCMV infection leads to a steady increase
of ZAP-S levels, while ZAP-L is already expressed in uninfected cells but also further
induced upon infection and is overall stable throughout a complete cycle of HCMV
replication.
Both ZAP-S and ZAP-L negatively affect HCMV genome replication. To investi-
gate the impact of ZAP on HCMV replication, WT, control, or ZAP KO HFF-1 cells were
infected with HCMV, and viral genome copies were quantified by quantitative PCR at
1, 3, and 5 days postinfection (dpi) (Fig. 2A). We included day 1 of infection in our anal-
ysis to verify that the KO of ZAP is not affecting viral entry and that the different cell
lines were infected to a similar extent. Indeed, at this early time point when HCMV has
not entered the first round of viral genome replication, no significant differences in the
number of HCMV genome copies were detected (Fig. 2B). At day 3 postinfection, when
HCMV has completed its first replication cycle, WT and control cells showed signifi-
cantly lower numbers of viral genome copies compared to ZAP KO cells. At 5 days
postinfection, HCMV genome copy numbers in WT and control cells were still 5 times
lower than those in ZAP KO cells (Fig. 2B). These results suggest that HCMV genome
replication is negatively affected by ZAP-S, ZAP-L, or both.
Next, we sought to elucidate which of the two major isoforms contributes to the
restriction of HCMV replication. To address this, we reconstituted ZAP KO cells by lenti-
viral transduction with either an empty vector control or C-terminally myc-tagged
forms of ZAP-S or ZAP-L (Fig. 2C). Both ZAP isoforms were codon optimized to avoid
recognition and cleavage by the stably expressed guide RNA (gRNA) and Cas9 within
the KO cell lines. Protein levels of both codon-optimized and WT isoforms were compa-
rable when expressed in HEK 293T cells, showing that codon optimization of the ZAP-S
or ZAP-L gene did not negatively affect protein expression (Fig. S1). Upon stable
expression in ZAP KO HFF-1 cells, both ZAP-S and ZAP-L localized to the cytoplasm
under both uninfected and infected conditions (Fig. 2D). Next, the reconstituted ZAP
KO cells were infected with HCMV, and genome copy numbers were analyzed as
described above (Fig. 2A). Strikingly, reconstitution with either ZAP-S (Fig. 2E) or ZAP-L
(Fig. 2F) in ZAP KO cells rescued the phenotype. While HCMV genome copy numbers
were equal in infected WT and ZAP-S or ZAP-L reconstituted cells, ZAP KO cells showed
significantly higher viral copy numbers. To exclude the possibility that the C-terminal
myc-tag of ZAP-L could be interfering with the CaaX prenylation motif and therefore
with prenylation of ZAP-L and its correct subcellular localization, we analyzed the viral
genome copy numbers in ZAP KO cells expressing an untagged version of ZAP-L. As
shown in Fig. S2A, myc-tagged and untagged ZAP-L had similar effects on HCMV
replication.
Taken together, these findings show that both ZAP-S and ZAP-L negatively affect
HCMV genome replication.
ZAP negatively affects global expression of early and late HCMV proteins.
Given the negative impact of ZAP on HCMV genome replication, we next examined
the time course of HCMV infection in the presence or absence of ZAP. Expression of
HCMV genes follows a temporal cascade, which begins with the transcription of imme-
diate-early (IE) genes, with the translation of IE proteins starting approximately 6 h
postinfection (hpi). IE proteins subsequently transactivate the transcription of early (E)
genes, which are mainly involved in viral DNA replication. Early proteins are produced
approximately 18 to 20 hpi and together with a third classical cluster of the so-called
early-late (E-L) proteins at 48 hpi will mediate the transcription of late (L) genes, which
code mainly for viral capsid, envelope, and tegument components at 72 to 96 hpi
(32–34). When we monitored the expression levels of the early viral protein UL44 and
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FIG 2 ZAP-S and ZAP-L restrict HCMV replication in HFF-1 cells. (A) Schematic representation of the workflow to
determine HCMV genome copy numbers. WT, control, or ZAP KO HFF-1 cells were infected with HCMV (MOI 0.1) for
2 h. Both cells and supernatant were harvested at 1, 3, and 5days postinfection (dpi), followed by DNA extraction and
measurement of viral genome copies by quantitative PCR. (B) HCMV genome copy numbers from WT, control, or ZAP
KO HFF-1 cells were determined as described in panel A. HCMV copy numbers/ml are displayed as bar plots showing
the mean 6 standard deviation (S.D.) of biological triplicates. Results shown are one representative of at least three
independent experiments using two different ZAP KO cell lines, with similar results obtained in all replicates. (C)
Schematic representation of the workflow to reconstitute ZAP KO HFF-1 cells. HEK 293T cells were transfected with
either myc-tagged ZAP-S or ZAP-L expression plasmids together with the packaging (gag-pol) and the envelope (VSV-
G) plasmids to produce lentiviruses harboring ZAP-S or ZAP-L, respectively, followed by transduction of ZAP KO HFF-1
cells. As the control, WT and ZAP KO HFF-1 cells were transduced with lentiviruses harboring empty vector. (D)
Subcellular localization of myc-tagged ZAP-S and ZAP-L in ZAP KO HFF-1 cells. ZAP KO cells were transduced as
described in panel C with either myc-tagged ZAP-S or ZAP-L. Transduced cells were infected by centrifugal
enhancement with HCMV (MOI 0.1), and 24 h postinfection, cells were fixed for immunolabeling with myc- and HCMV
IE1-specific antibodies. IE1, immediate-early protein 1. Nuclei were stained with Hoechst 33342. Scale bars represent
50mm. (E and F) HCMV genome copy numbers from WT, ZAP KO, or ZAP KO HFF-1 cells reconstituted with ZAP-S (E)
or ZAP-L (F) were determined as described in panel A. HCMV copy numbers/ml are displayed as bar plots showing the
mean 6 S.D. of one (E) or two combined independent (F) experiments performed with biological triplicates. Two
independent experiments for both ZAP-S and ZAP-L were performed. Significant changes were calculated using
unpaired two-sided Student’s t tests, n.s., not significant; *, P, 0.05; **, P, 0.01; ***, P, 0.001; ****, P, 0.0001.
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the late viral protein UL83 in HCMV-infected WT and the three ZAP KO cell lines, we
observed elevated protein levels of UL44 and UL83 in the absence of ZAP. This sug-
gests that the presence of ZAP negatively affects viral protein expression (Fig. 3A),
which is in line with our analysis of HCMV genome replication (Fig. 2B).
To obtain a global overview of the progression of HCMV infection, we performed
whole-proteome analyses of WT and ZAP KO HFF-1 cells using liquid chromatography
with tandem mass spectrometry (LC-MS/MS) (Data set S1). We mock-treated or
infected WT and ZAP KO HFF-1 cells with HCMV for 48 and 72 h, thus covering the early
and late proteome landscape of viral gene expression. Overall, we observed signifi-
cantly higher viral protein levels in ZAP KO cells than in WT cells (Fig. 3B). In line with
our previous observations (Fig. 3A), we detected significantly higher levels of the early
UL44 protein and the late UL83 protein in ZAP KO cells (Fig. 3C). Moreover, the pro-
teome analysis showed other viral proteins that were significantly upregulated in the
absence of ZAP. For instance, we detected increased expression of UL84, which is an
early protein involved in viral DNA replication, at 48 hpi (Fig. 3D), as well as elevated
levels of the late proteins UL103 and UL104 at 72 hpi, similar to UL83 and correspond-
ing to late kinetics (Fig. 3E).
Next, we performed reconstitution assays with myc-tagged ZAP-S and ZAP-L as
described above (Fig. 2C) and analyzed UL44 protein expression by immunoblotting
(Fig. 3F and G). Similar to our analysis of HCMV genome replication, UL44 protein levels
in ZAP KO cells reconstituted with either myc-tagged ZAP-S (Fig. 3F) or myc-tagged
ZAP-L (Fig. 3G) were lower than in the absence of ZAP and comparable to those in WT
cells. Similar results were obtained with untagged ZAP-L (Fig. S2B).
Taken together, these results demonstrate that the presence of both main ZAP iso-
forms negatively affects HCMV protein levels at early and late stages of infection.
ZAP-S and ZAP-L have a negative impact on early and late HCMV transcripts.
Previous studies showed that ZAP directly binds to RNA (14) and subsequently medi-
ates its degradation by recruiting both the 59and 39 RNA degradation machinery (13,
16). To decipher whether ZAP affects HCMV mRNA expression, we analyzed mRNA lev-
els of the early UL44 and the late UL83 transcripts at different stages of the HCMV infec-
tion cycle by quantitative reverse transcription-PCR (qRT-PCR) in WT and ZAP KO cells.
Indeed, in the presence of ZAP, UL44 and UL83mRNA levels were lower (Fig. 4A), which
mirrors our protein analyses. Congruent with our analysis of HCMV protein expression
(Fig. 3), reconstitution of ZAP KO cells with either ZAP-S or ZAP-L resulted in the rescue
of this phenotype (Fig. 4B).
Taken together, these results suggest that both ZAP isoforms, ZAP-S and ZAP-L,
negatively regulate HCMV mRNA expression, possibly by affecting either their expres-
sion or stability or by other, indirect effects.
HCMV infection progresses faster in the absence of ZAP. In order to understand
the effect of ZAP on the viral gene expression cascade over time, we analyzed the
whole-transcriptome landscape during HCMV infection by RNA-sequencing (RNA-seq)
in WT, control cells, and two independent ZAP KO cell lines (g1 and g3 ZAP KO)
(Fig. 5A, Data set S2). First, we observed that HCMV infection leads to a robust and
overall similar induction of ISGs in all cell lines analyzed, indicating that the absence of
ZAP does not affect the PRR-mediated host response during HCMV infection (Fig. S3).
For analysis of the temporal progression of HCMV gene expression, we focused on the
mRNA abundance per time point postinfection relative to the abundance over all time
points. Based on these relative temporal gene expression values in WT cells, genes
were clustered into nine groups grouped from immediate-early to late expression,
broadly corresponding to a previously published classification (32) (Fig. 5A, Fig. S4). To
simplify the temporal distribution of the viral genes, average relative expression levels
of the genes within the clusters were calculated and depicted as a heat map (Fig. 5A).
Strikingly, the temporal expression patterns of most clusters were shifted to earlier
time points in both ZAP KO cell lines compared to WT and control cells. For instance,
ZAP KO cells showed high expression levels of UL138 or long noncoding RNA 2.7
(Fig. S4). Notably, these viral transcripts have been previously identified in several
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FIG 3 ZAP has a negative impact on early and late HCMV protein levels. (A) WT or ZAP KO HFF-1 cells were infected by centrifugal
enhancement with HCMV (MOI 0.1), and lysates were analyzed at the indicated time points postinfection by immunoblotting with specific
antibodies against HCMV UL44, HCMV UL83, and actin. One representative experiment performed with three independent ZAP KO cell lines
is shown, with similar results in all three experiments. Quantifications of UL44 and UL83 band intensities normalized to actin are represented
as bar plots. (B) WT and ZAP KO HFF-1 cells were mock-treated or infected by centrifugal enhancement with HCMV (MOI 0.1), and cell lysates
were subjected to total proteome LC-MS/MS analysis at the indicated time points. Represented are volcano plots (x axis, log2 fold change; y
axis, -log10 P value) showing differentially expressed proteins at 48 and 72 h post-HCMV infection (unpaired two-sided Student’s t test with
permutation-based FDR, 0.05; S0, 0.1). (C to E) Time-resolved expression changes of HCMV UL44 and UL83 (C), UL84 (D), UL103, or UL104 (E)
in HCMV-infected WT and ZAP KO HFF-1 cells displayed as bar plots showing the mean 6 S.D. of quadruplicates. (F and G) WT, ZAP KO, or
ZAP KO HFF-1 cells reconstituted with either ZAP-S (F) or ZAP-L (G) were infected by centrifugal enhancement with HCMV (MOI 0.1), and
lysates were analyzed at the indicated time points postinfection by immunoblotting with specific antibodies against ZAP, HCMV UL44, and
actin. Quantifications of UL44 band intensities normalized to actin are depicted as bar plots. One representative of at least 2 independent
experiments is shown. hpi, hours postinfection. Significant changes were calculated using unpaired two-sided Student’s t tests; n.s., not
significant; *, P, 0.05; **, P, 0.01; ***, P, 0.001.
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studies in relation to the latent phase of HCMV (35–37), a concept that is currently
changing and is increasingly associated with a late-lytic replication program (38).
Although the effect of earlier expression patterns in ZAP KO cells was not uniform, it
was particularly strong for cluster 7, which contains the genes UL141, US27, and US28,
and for cluster 8 (UL4, UL5, UL6, UL148A).
In conclusion, ZAP KO cells show an accelerated course of HCMV infection and
seem to more rapidly achieve an intracellular environment associated with a late-lytic
gene expression program. These results, in line with our findings for viral protein levels,
indicate that ZAP delays the progression of the HCMV infection cycle, as reflected in
the decelerated course of the viral gene expression cascade.
ZAP affects the stability of early, but not late, HCMV transcripts. ZAP was previ-
ously described to be involved in mRNA degradation. To investigate the mechanisms
by which ZAP interferes with HCMV infection, we analyzed cellular and viral mRNA sta-
bility during HCMV infection of WT and ZAP KO cells. For this, we labeled newly synthe-
sized RNA at 17 h or 71 h postinfection for 1 h with 4-thiouridine (4sU), as well as con-
trol untreated cells, and performed SLAM-seq (thiol-linked alkylation for the metabolic
sequencing of RNA) (39). Then, we identified the newly synthesized and total RNA
using the computational approach GRAND-SLAM (termed globally refined analysis of
newly transcribed RNA and decay rates using SLAM-seq) (40) (Fig. 5B, Data set S3). In
agreement with previous studies, we confirmed that TNFRSF10D total mRNA was signif-
icantly upregulated in uninfected ZAP KO cells but also expressed higher in the context
of HCMV infection (Fig. 5C). TNFRSF10D encodes the prosurvival protein TRAIL receptor
4 (TRAILR4, a human cell surface receptor of the TNF-receptor superfamily) and was
previously described to be targeted by ZAP at the mRNA level (41). Notably, we found
another, previously undescribed, antiapoptotic factor which was significantly upregu-
lated in ZAP KO cells compared to WT cells, ZMAT3 (encoding the zinc finger matrin-
type protein 3, also known as zinc finger protein Wig-1), with a more pronounced
FIG 4 ZAP-S and ZAP-L negatively affect early and late HCMV transcripts. (A) WT or ZAP KO HFF-1
cells were infected by centrifugal enhancement with HCMV (MOI 0.1). Total RNA was extracted at the
indicated time points postinfection, and mRNA levels of HCMV UL44 and UL83 were measured by
qRT-PCR. Viral mRNA relative expression (log10) normalized to GAPDH is displayed as bar plots
showing the mean 6 S.D. of three independent experiments performed with experimental duplicates.
Experiments were performed in three independent ZAP KO cell lines, and results were combined. (B)
ZAP KO HFF-1 stably expressing either ZAP-S or ZAP-L or transduced with empty vector control, and
WT cells expressing empty vector, were infected by centrifugal enhancement with HCMV (MOI 0.1)
and qRT-PCR performed as described in panel A. Viral mRNA relative expression (log10) normalized to
GAPDH is displayed as bar plots showing the mean 6 S.D. of two independent experiments
performed with experimental duplicates. hpi, hours postinfection. Significant changes were calculated
using unpaired two-sided Student’s t tests; n.s. not significant; *, P, 0.05; **, P, 0.01; ***, P, 0.001;
****, P, 0.0001.
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FIG 5 ZAP decelerates HCMV infection and negatively affects the stability of a subset of HCMV transcripts. (A) WT, control, and two independent
ZAP KO HFF-1 cell lines were untreated (UT), mock-treated, or infected by centrifugal enhancement with HCMV (MOI 0.1). Total RNA was extracted
at 8, 24, and 72 hpi, and lysates were subjected to total transcriptome analysis. Relative temporal expression levels of gene clusters and selected
individual genes are represented as a heat map. Expression of HCMV genes was quantified from the RNA-sequencing and relative temporal
expression levels calculated by dividing, per-sample, normalized expression values (fpkm) to the sum of these values from the same gene over all
samples/time points. Based on these values, genes were clustered in nine groups representing kinetic classes. Shown are the averages of replicates
and clusters. g1, g3, ZAP KO generated with gRNA 1 or gRNA 3. (B) WT and ZAP KO HFF-1 cells were left untreated (UT) or infected by centrifugal
enhancement with HCMV (MOI 0.1). Newly synthesized RNA was labeled with 4-thiouridine (4sU) for 1 h prior to cell lysis, and lysates were taken
at 18 and 72 hpi, followed by RNA purification. SLAM-seq was performed to identify newly synthesized and total RNA using GRAND-SLAM. (C)
Time courses of log2 fold changes of cellular and viral genes (n=12,652) for total (upper panel) and newly synthesized (lower panel) RNA in ZAP
KO/WT HFF-1 cells. The values represent the mean of two biological replicates. TNFRSF10D and ZMAT3 are indicated in yellow and purple,
respectively. (D and E) Represented are log2 fold changes of cellular and viral genes (n=12,652) for total (x axis) and newly synthesized RNA (y axis)
at 72 (D) and 18 hpi (E). Values represent the mean of two biological replicates. Weakly expressed viral genes are indicated (,10 TPM). Dashed
lines demarcate 2-fold differences in regulation of total versus newly synthesized RNA. hpi, hours postinfection; TPM, transcripts per million.
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upregulation in the context of HCMV infection (Fig. 5C, Fig. S5). For both TNFRSF10D
and ZMAT3, reconstitution with either ZAP-S or ZAP-L rescued these phenotypes as
shown by qRT-PCR analyses (Fig. S5). The SLAM-seq results revealed that the upregula-
tion in ZAP KO cells of these two cellular mRNAs in total RNA was not paralleled by the
transcription of newly synthesized RNA, where levels were equal between WT and ZAP
KO cells (Fig. 5C). This shows that in the absence of ZAP, these transcripts have a longer
half-life and indicates that ZAP has an impact on their degradation, but not on their
transcription.
For viral mRNA transcripts, we observed a 4- to 12-fold upregulation in ZAP KO cells
on both total RNA as well as newly synthesized RNA levels at 72 hpi (Fig. 5D). These
results indicate that the upregulation on total RNA levels in ZAP KO cells at late times
of HCMV infection is predominantly due to increased transcription rates and not due
to an increase in mRNA stability.
At 18 hpi, upregulation of viral transcripts was much weaker and below 2-fold for
genes with significant levels of expression (.10 transcripts per million, TPM), with the
exception of UL4 and UL5, which were 6-fold upregulated (Fig. 5E). Strikingly, the up-
regulation in total RNA was not paralleled by upregulation of newly synthesized RNA.
This provides evidence that at 18 hpi, a small subset of viral transcripts, including UL4
and UL5, is destabilized in the presence of ZAP. We conclude that ZAP directly inter-
feres with the expression of distinct viral genes early during infection on the posttran-
scriptional level, which, as a secondary effect, results in substantially weaker transcrip-
tion of viral genes at later time points.
ZAP binds to cytosine-rich regions in several thousand cellular mRNAs.
Previous studies indicated that ZAP directly binds to CG-dinucleotide-enriched RNA
sequences (19, 29). To determine the physical mRNA binding sites of ZAP during
HCMV infection, we performed enhanced cross-linking and immunoprecipitation in
combination with RNA sequencing analysis (eCLIP-seq) (42) using a ZAP antibody that
recognizes both ZAP isoforms (Fig. 6A). We first concentrated on the host genome
where we found 15,302 ZAP binding sites in 5,657 transcripts (Data set S4). To assess
the quality of our data, we compared the expression changes of cellular mRNAs with
and without ZAP binding sites in WT and ZAP KO cells. For that, we focused on the
untreated samples from our SLAM-seq experiment to exclude effects of ZAP that are
not mediated by direct interaction with targets, which likely are exacerbated upon
infection. Gene expression differences were generally weak, with .95% of genes regu-
lated less than 1.3-fold. Nevertheless, genes with a strong ZAP binding site (.5-fold
enrichment of size-matched input RNA) or with multiple binding sites had on average
higher expression levels in KO cells (P, 6.4 1026, two-sided Kolmogorov-Smirnov
test.) (Figure S6A). In contrast, newly synthesized RNA was largely unchanged
(Fig. S6B). This shows that even in uninfected cells, ZAP has a measurable impact on
RNA half-lives of hundreds of cellular genes and that our eCLIP approach could capture
the global landscape of ZAP binding sites. For genes with a single weak binding site of
ZAP (,5-fold enrichment over input RNA), we did not observe an effect on expression
levels (Fig. S6A). Weak binding sites might correspond to transient ZAP binding with-
out a strong effect on RNA stability, or they are predominantly false-positive peak calls.
Thus, we concentrated on strong ZAP binding sites in the following analyses.
To evaluate the binding preferences of ZAP in our data, we counted dinucleotides
inside or outside binding sites in strongly expressed genes (TPM. 10, n=6,600) at 18
hpi. As observed in previous studies, CG dinucleotides in ZAP binding sites were signifi-
cantly overrepresented (enrichment over background f=1.65, P, 2 10216, two-sided
Wilcoxon test). However, we also observed other cytosine-containing dinucleotides,
including CC (f=1.55, P, 2 10216), TC (f=1.48, P, 2 10216), and CT (f=1.46,
P, 2 10216), to be strongly enriched in binding sites. In contrast, adenosine-contain-
ing dinucleotides, with the exception of TA, were generally underrepresented (AA,
f=0.46; GA, f=0.62; AG, f= 0.67; AT, f=0.75; CA, f=0.78; AC, f=0.80; all, P, 2 10216;
Fig. 6B).
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FIG 6 ZAP specifically binds to a subset of cytosine-rich viral transcripts early during HCMV infection. (A) WT HFF-1 cells were infected with HCMV (MOI 1)
and UV-cross-linked 20 hpi to create covalent bonds between nucleic acids and associated proteins. Following cell lysis, unprotected RNA was digested
and endogenous ZAP was immunoprecipitated using a ZAP-specific antibody. Cross-linked protein-RNA complexes were separated by SDS-PAGE, followed
by transfer onto nitrocellulose. Bands migrating at the expected size range were excised, and recovered RNA fragments were converted into a cDNA
library. IP samples and size-matched input were subjected to sequencing according to the eCLIP protocol. The cross-linking site is depicted as a star. (B)
Boxplots showing the distribution of relative frequencies of dinucleotides inside (“binding site”) and outside (“background”) binding sites for n= 6,600
strongly expressed genes (TPM. 10). The y axis is cut at 0.2. (C) Heat map showing the log2 enrichments of dinucleotide frequencies over background at
each position upstream and downstream of the main cross-linking site per gene (n= 6,600). (D) Scatterplot comparing the deviation of KO versus WT fold
changes in newly synthesized RNA from total RNA against the total expression level in WT at 18 h postinfection (hpi). Viral open reading frames (ORFs) are
colored according to their strongest binding site (in terms of enrichment over input RNA) or shown in black if no binding site was detected. Cellular genes
are shown in gray for comparison. TPM, transcripts per million. (E) Genome browser showing the UL4-UL6 locus. The tracks indicate the position in the
HCMV genome, the ORF positions, polyadenylation signals (PAS), binding sites called by MACS2 with the indicated enrichment values, the normalized
coverage of eCLIP reads (input in ochre, IP in green), and the normalized coverage by SLAM-seq reads at 18 h postinfection (ZAP KO cells in red, WT cells
in gray).
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To investigate the binding preferences of ZAP in more detail, we made use of the
nucleotide resolution of our eCLIP data; for each gene with a detected binding site, we
identified the strongest cross-linking site by considering the 39 ends of mapped eCLIP
read pairs and counted occurrences of dinucleotides around these sites. This more
detailed analysis confirmed the over- and underrepresentation of specific dinucleoti-
des. Moreover, it revealed much stronger enrichments of cytosine-containing dinucleo-
tides at specific positions downstream of the cross-linking sites than predicted by the
prior analysis (CG, f=2.08; CC, f=2.00; TC, f=1.77; CT, f=1.67) and much stronger
depletion of adenosine-containing dinucleotides (CA, f=0.13; AA, f=0.20; AT, f=0.31;
AC, f=0.51; GA, f=0.51; AG, f=0.53; Fig. 6C). We then used DREME (43) to identify
motifs enriched in the sequences directly downstream of the main cross-linking site.
However, only a few spurious motifs were identified (Fig. S6C to E). As these were
largely composed of overrepresented dinucleotides, we concluded that ZAP preferen-
tially binds to cytosine-rich regions devoid of adenosines but likely does not recognize
longer sequence patterns.
ZAP binds to a limited number of sites in the viral transcriptome to destabilize
mRNAs transcribed from the UL4-UL6 locus. Next, we identified ZAP binding sites in
the viral transcriptome and mapped them to open reading frames (ORFs). Interestingly,
we found only 16 binding sites exceeding an enrichment of .5-fold over input, 12 of
which could be mapped to an ORF of the HCMV genome (Data set S4). Of note, five of
those mapped to the UL4-UL6 locus. Thus, ZAP binds to only a small number of sites on
viral mRNAs, and those are concentrated in the UL4-UL6 locus.
We then aimed to directly compare the ZAP binding sites identified by eCLIP with
the regulation at 18 hpi. For that, we plotted the log fold change difference in total
versus newly synthesized RNA (i.e., the deviation from the diagonal line in Fig. 5E)
against the overall expression strength in the WT and determined for each ORF the
most strongly enriched binding site (Fig. 6D). As shown before, transcripts expressed
from the UL4-UL6 locus were by far the most strongly destabilized mRNAs (Fig. 5E),
with a strong temporal shift upon ZAP depletion (Fig. 5A, Fig. S4, cluster 8). Strikingly,
our analysis revealed that these transcripts are also the only direct targets of ZAP with
a substantial enrichment over input as shown by eCLIP-seq (Fig. 6E). Our SLAM-seq
data indicate that transcription at this locus stops at a polyadenylation signal inside
the UL6 ORF and that a sixth binding site upstream of the UL4 ORF that was not con-
sidered in the previous analysis is also located on a transcript expressed from this locus
(Fig. 6E).
Altogether, our data provide clear evidence that ZAP strongly destabilizes mRNAs
originating from the UL4 and UL5 ORFs by directly binding to several mRNA sites and
that these are the most prominent ZAP targets among the transcripts produced from
the HCMV genome. We therefore propose that this early and distinct regulation of the
UL4-UL6 locus early after HCMV infection could underlie the observed delay in the pro-
gression of the HCMV infection cycle (Fig. 7).
DISCUSSION
Viral infection induces a specific expression pattern of ISGs (44). To date, more than
300 ISGs have been described, but so far, the function of the majority of the proteins
they encode is poorly understood. ISG function is highly contextual, as their effect on
viral infection is dependent on the viral entry route, replication mechanism, site of rep-
lication and viral assembly, and cell type. Hence, while some ISGs may exert an antiviral
activity against some viruses, they may either have a neutral or positive effect on other
viruses or, in some instances, be susceptible to viral evasion mechanisms (5, 7).
HCMV infection leads to the upregulation of a distinct set of cellular proteins during
the first 24 h of infection, 32 of which were classified as ISGs, including the RNA bind-
ing protein ZAP (32). While that report did not distinguish between the two major ZAP
isoforms, ZAP-S and ZAP-L, in this study, we delineated their endogenous expression
kinetics during HCMV infection. ZAP-L is readily detectable in uninfected cells, and its
expression slightly increases throughout the first 48 h of HCMV infection, while ZAP-S
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protein levels are low in uninfected cells and strongly upregulated from 6h postinfec-
tion onward. At a late stage of the HCMV life cycle, expression of both ZAP isoforms
decreases, which likely reflects the fading type I IFN response rather than HCMV-medi-
ated degradation (32, 45).
Our results showed that HCMV replication is restricted by the presence of ZAP.
Notably, reconstitution of ZAP KO cells with either ZAP-S or ZAP-L showed that both
have the potential to restrict HCMV replication to similar levels as endogenous ZAP in
wild-type cells. However, the overexpression of one or another ZAP isoform during
reconstitution did not push antiviral protection beyond that of endogenous levels. We
speculate that this could (i) be a phenomenon of saturation regarding the capacity of
cellular machineries to degrade RNA or (ii) be related to the availability of cofactors
involved in ZAP-mediated antiviral activities (46–48).
While both ZAP isoforms, ZAP-S and ZAP-L, restricted HCMV infection in our study,
recent studies propose diverse functions for one or the other isoform during infection
with different viruses, for example, the DNA virus modified vaccinia virus Ankara (MVA)
(27) and Sindbis virus (SINV), an RNA alphavirus (17, 31). For MVA, which replicates in the
cytoplasm, no impact of ZAP on viral transcription was observed, but rather, an effect of
FIG 7 ZAP is a restriction factor for HCMV infection. (A) The expression of the ISG ZAP is induced at
early stages during HCMV infection. The RNA-binding protein ZAP specifically binds to viral mRNAs
transcribed from the HCMV UL4-UL6 genome locus (depicted in orange) and negatively affects their
stability. In the presence of ZAP, expression of early and late HCMV genes and proteins, as well as
genome replication, is delayed. (B) In the absence of ZAP, the stability of HCMV mRNAs transcribed
from the UL4-UL6 locus is unaltered, and HCMV transcription, protein expression, and genome
replication are enhanced compared to ZAP-expressing cells.
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ZAP-L on viral assembly was observed (27). Similarly, Schwerk and colleagues found that
ZAP-L, which can be farnesylated at its C terminus (lacking in ZAP-S) and is thereby tar-
geted to membranes (10), colocalizes with SINV RNA intermediates in distinct foci in the
cytoplasm (31). Moreover, ZAP-S was described to act as a negative feedback regulator
of the IFN response later in infection with SINV by destabilizing IFN transcripts (31).
However, in our study, by comparing WT and ZAP KO cells, we did not observe an effect
of ZAP expression on IFN signaling pathways. This could be due to the presence of
HCMV evasion proteins that downmodulate the IFN response, which may overshadow
an effect of ZAP-S in this regard (7, 49), but this is purely speculative at this point.
Nevertheless, based on our results, we cannot state whether ZAP-S and ZAP-L employ
the same mechanism of action or whether they provide individual contributions to in-
hibit HCMV replication. This will need to be further evaluated in future work.
We took a global approach to explore the role of ZAP during HCMV infection and
examined the whole transcriptome and proteome in WT and ZAP KO cells. We
observed that expression of ZAP greatly delays transcription of the majority of viral
genes, eventually resulting in a delay of viral protein expression. CCCH-type zinc finger
proteins such as ZAP have previously been reported to be capable of RNA binding and
mediation of RNA degradation (13, 14, 16). In the case of ZAP, a preference for RNA
with a high CG dinucleotide content was proposed (19, 20, 30). In comparison to the
human genome, which has low CG content (50, 51), the HCMV genome presents the
highest CG content among human Betaherpesvirinae (52), which makes HCMV tran-
scripts a putative target for ZAP-mediated degradation. Accordingly, we conducted a
series of experiments with regard to mRNA stability during HCMV infection. By per-
forming eCLIP-seq and SLAM-seq, we investigated whether (i) ZAP binds to cellular
and/or viral mRNA, (ii) ZAP binds to specific mRNA sequences, and (iii) the stability of
the ZAP-bound mRNA is altered.
First, due to the nucleotide resolution of eCLIP-seq, dinucleotide analyses carried
out on the strongest cross-linking sites enabled the identification of putative binding
preferences for ZAP. The obtained results were in agreement with previous publica-
tions that show a binding preference of ZAP to CG-rich motifs (19, 20, 29, 30, 53).
However, our analysis revealed that not only CG, but also other cytosine-containing
dinucleotides were highly overrepresented in the cross-linking sites, whereas adeno-
sines were significantly underrepresented. Ultimately, our data did not provide specific
sequence motifs for ZAP binding, but only few spurious motifs were identified. As
these were largely composed of overrepresented dinucleotides, we conclude that ZAP
likely does not recognize longer specific sequence patterns but preferentially binds to
cytosine-rich regions. At this point, we can only hypothesize that there may also be (i)
sequences surrounding the ZAP binding sites or (ii) secondary RNA structures that are
crucial for ZAP binding, as previously proposed by Huang et al. (28). These results also
suggest a broader binding preference of ZAP to mRNA, which in turn, possibly allows
ZAP to act against a variety of viruses, and virus-mediated escape of recognition by
ZAP, e.g., by single nucleotide mutations, is less likely.
In agreement with previous studies, which described ZAP to mediate degradation
not only of foreign but also of specific cellular transcripts (31, 41), we identified thou-
sands of ZAP-bound cellular transcripts by eCLIP-seq. These transcripts were weakly
but significantly downregulated in uninfected WT cells, indicating that ZAP, even when
expressed at basal levels in interferon-naive cells, exerts a function as an mRNA desta-
bilizer. Upon HCMV infection, several cellular mRNAs were strongly destabilized by
ZAP. For example, we confirmed a previously reported negative effect of ZAP on
TNFRSF10D (41), encoding the TRAIL receptor 4 (TRAILR4) involved in cell survival. The
authors showed that ZAP-mediated downregulation of TRAILR4 results in increased
cell sensitivity to TRAIL-mediated apoptosis (41). Moreover, our global approach
allowed us to identify previously undescribed cellular targets of ZAP, as illustrated by
the ZMAT3 gene, encoding the zinc finger matrin-type protein 3 (also known as zinc
finger protein Wig-1), which is another prosurvival factor (54).
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As mentioned above, the HCMV genome has a high CG content compared to the
host genome. However, expression of ZAP did not affect stability of viral transcripts
expressed late in infection (72 hpi), but it affected viral transcripts expressed at early
stages of infection (18 hpi), with HCMV UL4 and UL5 transcripts being the most promi-
nent ones. Remarkably, eCLIP-seq revealed that most of the binding sites for ZAP were
concentrated in the UL4-UL6 locus. This strongly suggests that the overall CG content
is not predictive for ZAP binding.
In the course of completing our manuscript, a study was published that reported a
negative effect of ZAP on HCMV (25). The authors concluded, based on a bioinformatics
analysis of the CG content of HCMV genes, that the low CG content of the IE1 gene could
be an HCMV evasion mechanism to avoid ZAP recognition (25). While the conclusion
drawn by Lin et al. (25) is reasonably supported by their data, the impact of ZAP was
only elucidated on four HCMV proteins, without analyzing their transcript levels or
mRNA stability. Our study generally confirmed the results of Lin et al. (25), as we did
observe a ZAP-dependent notable delay of viral protein expression but no effect on total
IE1 transcript levels. However, rather than IE1 expression being the decisive factor for
this phenotype, our data suggest that the delay in HCMV life cycle progression is due to
the effect of ZAP on the stability of transcripts from the UL4-UL6 gene locus.
UL4, UL5, and UL6 belong to the RL11 gene family of HCMV (55, 56). The UL4 gene
encodes two transcripts with early kinetics and one with late kinetics (57, 58), while
UL5 encodes two transcripts (59, 60). Interestingly, all of them share the same 39 end,
which designates the UL4-UL5 region as a transcription unit (60). To our knowledge,
UL6 was not further characterized yet. The biological function of the RL11 family mem-
bers is only poorly understood. Several studies suggest that these membrane-associ-
ated proteins may be involved in immune evasion (61–65), as they are largely dispen-
sable for virus growth in cultured fibroblasts (66, 67). A more detailed impact of UL4
and UL6 on HCMV infection has not been studied so far. Recently, HCMV UL5 was
shown to be involved in efficient viral assembly and/or egress from the host cell by
interacting with the cellular scaffold protein IQGAP1 (IQ motif-containing GTPase acti-
vating protein 1) (68). This indicates a possible role of UL5 in a late phase of HCMV
infection. However, the impact of UL4 and UL5 expressed with early kinetics remains
unknown. The fact that ZAP has an impact on HCMV infection and specifically targets
transcripts from this locus suggests a possible involvement of products originating
from the UL4-UL6 gene locus for efficient HCMV infection.
Altogether, these findings show the multiple layers of complexity of the RNA bind-
ing protein ZAP, highlighting its different facets depending on the virus species it
encounters. For HCMV, ZAP appears on the scene at early time points of infection,
decelerating the viral gene expression cascade, presumably by handpicking a distinct
set of viral transcripts for degradation, mainly containing the UL4 and UL5 HCMV ORFs.
Our study illustrates the potent role of ZAP as an antiviral restriction factor and sheds
light on a possible role of UL4 and/or UL5 early during infection, paving a new avenue
to explore these poorly characterized HCMV genes.
MATERIALS ANDMETHODS
Cell lines. Primary human foreskin fibroblasts (HFF-1; SCRC-1041), MRC-5 (CCL-171), and human em-
bryonic kidney 293T cells (HEK 293T; CRL-3216) were obtained from ATCC. HEK 293T and MRC-5 cells
were maintained in Dulbecco’s modified Eagle’s medium (DMEM; high glucose) supplemented with 8%
fetal calf serum (FCS) and 1% penicillin/streptomycin (P/S). HFF-1 cells were maintained in DMEM (high
glucose) supplemented with 15% FCS, 1% P/S and 1% nonessential amino acids (NEAA). Cells were cul-
tured at 37°C in a humidified 7.5% CO2 incubator.
Viruses. The wild-type HCMV TB40-BAC4 (here designated HCMV WT) was characterized previously
(69) and kindly provided by Martin Messerle (Institute of Virology, Hannover Medical School, Germany).
HCMV BACs were reconstituted after transfection of MRC5 cells with purified BAC DNA. Reconstituted vi-
rus was propagated in HFF-1 cells, and virus was purified on a 10% Nycodenz cushion. The resulting vi-
rus pellets were resuspended in virus standard buffer (50mM Tris-HCl pH 7.8, 12mM KCl, 5mM EDTA)
and stored at 270°C. Infectious titer was determined by standard plaque assay and IE1 labeling using
HFF-1 cells.
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Plasmids. Expression plasmids for firefly luciferase (FFLuc, control) and ZAP-S (short isoform of ZAP)
in pTRIP-IRES-RFP as well as pCMV-VSV-G and pCMV-gag/pol plasmids were described previously (44)
and kindly provided by John Schoggins (University of Texas Southwestern Medical Center, Dallas, Texas).
pcDNA4-HA-ZAP-L (long isoform of ZAP) (9) was kindly provided by Chad Swanson (Department of
Infectious Diseases, School of Immunology and Microbial Sciences, King’s College London). ZAP-S and
ZAP-L were subcloned into pEF1-V5/His (Thermo Fisher Scientific) via the KpnI/XbaI sites to generate
pEF1-ZAP-S-V5/His and pEF1-ZAP-L-V5/His, respectively. Exchange of V5/His to myc/His was performed
using the Q5 site-directed mutagenesis kit (New England Biolabs [NEB] no. E0554) according to the man-
ufacturer’s protocol, resulting in pEF1-ZAP-S-myc/His and pEF1-ZAP-L-myc/His. In order to reconstitute
ZAP-S and ZAP-L expression in ZAP KO cell lines, codon optimization of the ZAP-S and ZAP-L coding
region was performed to prevent binding of the constitutively expressed gRNA and Cas9. For this, nucle-
otides 103 to 219 of the ZAP-S and ZAP-L coding region (spanning the binding sites for gRNA 1 and
gRNA 3; see Fig. 1C) were codon optimized using the Q5 site-directed mutagenesis kit, resulting in
pEF1-ZAP-S-myc/His and pEF1-ZAP-L-myc/His codon-optimized. A pTRIP-IRES-RFP empty vector was
generated by replacing the coding region of ZAP-S from pTRIP-IRES-RFP ZAP-S (received from John
Schoggins) by the multiple cloning sites of pWPI vectors to obtain PmeI, SdaI, SgsI, BamHI, XmaI, RgaI,
and XhoI restriction sites for further subcloning. Codon-optimized versions of ZAP-S and ZAP-L were
subcloned into the newly generated pTRIP-IRES-RFP empty vector via the SgsI/BamHI restriction sites to
generate pTRIP-IRES-RFP ZAP-S-opt-myc/His and pTRIP-IRES-RFP ZAP-L-opt-myc/His. To generate the
untagged version of ZAP-L, ZAP-L optimized was subcloned into pTRIP-IRES-RFP empty vector via the
PmeI/BamHI sites, resulting in pTRIP-IRES-RFP ZAP-L-opt. All constructs were verified by sequencing.
Oligo sequences as well as sequences of all constructs are available upon request.
The expression plasmid for gRNA cloning and CRISPR/Cas9-mediated gene editing, pLK05.U6.sgRNA
(BsmBI,stuffer).EFS.SpCas9.P2A.tagRFP (70), was kindly provided by Dirk Heckl (Experimental Pediatrics,
Martin Luther University, Halle, Germany). The corresponding envelope and packaging plasmids, pMD2.
G and psPAX2, were purchased from AddGene (no. 12259 and no. 12260, respectively).
Antibodies and reagents. Mouse monoclonal anti-pp65 (anti-UL83) (no. ab6503, clone 3A12) was
obtained from Abcam, and mouse monoclonal anti-ICP36 (anti-UL44) (no. MBS530793, clone M612460)
was purchased from MyBioSource. Mouse monoclonal anti-hZAP (ZC3HAV1) (no. 66413-1-Ig, clone
1G10B9) and rabbit polyclonal anti-hZAP (no. 16820-1-AP) were obtained from ProteinTech. Mouse
monoclonal anti-actin (A5441, clone AC-15) was obtained from Sigma-Aldrich. Rabbit monoclonal anti-
myc (no. 2278, clone 71D10) was obtained from Cell Signaling. Mouse monoclonal anti-IE1 (clone 63-27,
originally described in reference 71) was a kind gift from Jens von Einem (Institute of Virology, Ulm
University Medical Center, Ulm, Germany). Alexa Fluor-conjugated secondary antibodies were purchased
from Invitrogen. The transfection reagent Lipofectamine 2000 was purchased from Life Technologies.
Polybrene was obtained from Santa Cruz Biotechnology. Opti-MEM was purchased from Thermo Fisher
Scientific. Protease inhibitors (no. 4693116001) were purchased from Roche. Recombinant human IFN-b
was purchased from PeproTech (no. 300-02BC).
Generation of ZAP knockout cells using CRISPR/Cas9-mediated genome editing. Custom gRNAs
targeting the first exon of the ZAP coding region, thus disrupting expression of ZAP-S and ZAP-L, were
designed using CRISPOR software (http://crispor.tefor.net) (72) and cloned into the lentiviral pLKO5 vec-
tor (kindly provided by Dirk Heckl, Martin Luther University, Halle, Germany). The pLKO5 vector constitu-
tively expresses the introduced gRNA under the control of a U6 promoter. SpCas9 with a P2A cleavage
site followed by RFP is under the control of the EF1a short promoter and results in the constitutive
expression of SpCas9 and an RFP reporter for cell sorting. Three different gRNAs targeting the ZAP coding
region and a nontargeting control gRNA were generated and cloned into the pLKO5 vector via the BsmBI
restriction site. ZAP gRNA 1 targets exon 1 at nucleotide 149, ZAP gRNA2 at nucleotide 53, and ZAP gRNA3
at nucleotide 191. The gRNA sequences are as follows: ZAP-g1_FOR, 59-CACCGGCCGGGCCCGACCGCTTTG;
ZAP-g1_REV, 59-AAACCAAAGCGGTCGGGCCCGGCC; ZAP-g2_FOR, 59-CACCGCAAAATCCTGTGCGCCCACG;
ZAP-g2_REV, 59-AAACCGTGGGCGCACAGGATTTTGC; ZAP-g3_FOR, 59-CACCGGCCGGGATCACCCGATCGG; ZAP-
g3_REV, 59-AAACCCGATCGGGTGATCCCGGCC; control-gRNA_FOR, 59-CACCGGATTCTAAAACGGATTACC; con-
trol-gRNA_REV, 59-AAACGGTAATCCGTTTTAGAATCC. For lentivirus production, HEK 293T cells (730,000 cells
per well, 6-well format) were transfected with 400ng pMD2.G, 1,600ng psPAX2, and 2,000ng pLKO5 plasmid
(containing the respective gRNA) complexed with Lipofectamine. Then, 16h posttransfection, medium was
changed to lentivirus harvest medium (DMEM h.gl. supplemented with 20% FCS, 1% P/S, and 10mM HEPES);
48h posttransfection, lentivirus was harvested and diluted 1:2 with HFF-1 medium, and Polybrene was added
to a final concentration of 4mg/ml. HFF-1 cells were seeded the day before transduction in a 6-well format
with 250,000 cells/well. For transduction, HFF-1 medium was replaced by medium containing lentivirus, and
cells were transduced by centrifugal enhancement at 684 g and 30°C for 90 min. Next, 3h postransduction,
medium was replenished with fresh HFF-1 medium. Successfully transduced cells were sorted by flow cytome-
try for RFP signal 72h postransduction to obtain a cell population devoid of ZAP expression. Cas9-mediated
knockout of ZAP was verified by immunoblotting.
Reconstitution assays. For reconstitution of ZAP-S or ZAP-L expression in ZAP KO cell lines, lentivi-
ral transduction was performed as described above. Briefly, 2,000 ng pTRIP-IRES-RFP empty vector or
pTRIP-IRES-RFP containing codon-optimized C-terminally myc-tagged ZAP-S, ZAP-L, or untagged ZAP-L,
together with 400 ng pCMV-VSV-G and 1,600 ng pCMV-gag/pol complexed with Lipofectamine was
transfected into HEK 293T cells, and medium was changed to lentivirus harvest medium the next day.
Then, 48 h posttransfection, the WT or the indicated ZAP KO HFF-1 cells were lentivirally transduced;
72 h postransduction, cells were counted, and 100,000 cells per well were seeded in a 24-well format.
The next day, cells were infected with HCMV WT at a multiplicity of infection (MOI) of 0.1, and infection
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was enhanced by centrifugation at 684 g for 45min at 30°C. After centrifugation, cells were incubated
at 37°C for 30min followed by replacement of virus-containing medium with fresh HFF-1 medium. At
the indicated time points postinfection, cells were lysed for analysis by immunoblotting or qRT-PCR as
described below.
Immunoblotting. For the analysis of viral protein kinetics upon HCMV infection, HFF-1 WT or ZAP
KO cells (100,000 cells/well in a 24-well format) were infected with HCMV WT at an MOI of 0.1, and the
infection was enhanced by centrifugation at 684 g at 30°C for 45min. The moment when the virus was
added to the cells was defined as time point 0. After centrifugation, cells were incubated at 37°C for 30
min followed by replacement of virus-containing medium with fresh HFF-1 medium. Cells were lysed at
the indicated time points using radioimmunoprecipitation (RIPA) buffer (20mM Tris-HCl pH 7.5, 1mM
EDTA, 100mM NaCl, 1% Triton X-100, 0.5% sodium deoxycholate, 0.1% SDS). Protease inhibitors were
added freshly to all lysis buffers prior to use. Cell lysates and samples were separated by SDS-PAGE and
transferred to polyvinylidene difluoride (PVDF) membrane (GE Healthcare) using wet transfer and
Towbin blotting buffer (25mM Tris, 192mM glycine, 20% [vol/vol] methanol). Membranes were probed
with the indicated primary antibodies and respective secondary horseradish peroxidase (HRP)-coupled
antibodies diluted in 5% wt/vol nonfat dry milk or 5% bovine serum albumin (BSA) in Tris-buffered saline
with Tween 20 (TBS-T). Immunoblots were developed using SuperSignal West Pico (Thermo Fisher
Scientific) chemiluminescence substrates. Membranes were imaged with a ChemoStar ECL imager
(INTAS) and quantified using LabImage 1D software (INTAS).
Immunofluorescence. ZAP KO HFF-1 cells were lentivirally transduced as described above. Briefly,
2,000 ng pTRIP-IRES-RFP containing codon-optimized C-terminally myc-tagged ZAP-S or ZAP-L together
with 400 ng pCMV-VSV-G and 1,600 ng pCMV-gag/pol complexed with Lipofectamine were transfected
into HEK 293T cells, and medium was changed to lentivirus harvest medium the next day. Then, 48 h
posttransfection, ZAP KO HFF-1 cells were lentivirally transduced; 72 h postransduction, cells were
counted, and 20,000 cells per well were seeded in a m-Slide 8-well chamber slide (ibidi; no. 80826). The
next day, cells were mock-infected or infected with HCMV WT at an MOI of 0.1, and infection was
enhanced by centrifugation at 684 g for 45min at 30°C. After centrifugation, cells were incubated at
37°C for 30min, followed by replacement of virus-containing medium with fresh HFF-1 medium. Cells
were fixed 24 hpi using 4% paraformaldehyde (PFA) in phosphate-buffered saline (PBS) for 20min at
room temperature. Cells were washed three times with PBS, followed by permeabilization using 0.4%
Triton X-100 in PBS for 10min at room temperature. Cells were washed three times with PBS and
blocked with 4% BSA in PBS for 45min. Cells were stained with the indicated primary antibodies and re-
spective secondary antibodies coupled to Alexa488, or Alexa647, and Hoechst (Thermo Fisher Scientific;
no. 33342) diluted in 4% BSA in PBS for 45min at room temperature in the dark. Imaging was done on a
Nikon ECLIPSE Ti-E-inverted microscope equipped with a spinning disk device (Perkin Elmer Ultraview),
and images were processed using Volocity software version 6.2.1 (Perkin Elmer).
Quantitative RT-PCR. HFF-1 WT or ZAP KO cells were infected with HCMV WT as described above.
Briefly, an MOI of 0.1 was used, and the infection was enhanced by centrifugation at 684 g at 30°C for
45min, followed by 30 min incubation at 37°C and replacement of virus-containing medium with fresh
HFF-1 medium. Cells were lysed in RLT buffer, and RNA was purified using the Analytik Jena RNA isola-
tion kit (845-KS-2040250) following the manufacturer’s protocol. After RNA extraction, 1,500 ng of RNA
per sample was used for further processing. DNase treatment and cDNA synthesis were performed with
the iScript gDNA Clear cDNA synthesis kit (no. 1725035) following the manufacture’s protocol. Generated
cDNA was diluted 1:5 before performing qPCR to obtain 100ml of cDNA. For quantification of gene tran-
scripts, 5ml of cDNA per sample was used, and qRT-PCR was performed using the GoTaq qPCR master mix
(Promega, A6001) on a LightCycler 96 instrument (Roche). GAPDH was used for normalization. The follow-
ing oligo sequences were used: GAPDH_FOR, 59-GAAGGTGAAGGTCGGAGTC; GAPDH_REV, 59-GAAGATG
GTGATGGGATTTC; UL44_FOR, 59-CGCGACGTTACTTTGATTTGAG; UL44_REV, 59-ATTCGGACGCCGACATTAG;
UL83_FOR, 59-AACCAAGATGCAGGTGATAGG; UL83_REV, 59-AGCGTGACGTGCATAAAGA; TNFRSF10D_FOR,
59-CTGCTGGTTCCAGTGAATGACG; TNFRSF10D_REV, 59-TTTTCGGAGCCCACCAGTTGGT; ZMAT3_FOR, 59-
GCTCTGTGATGCCTCCTTCAGT; ZMAT3_REV, 59-TTGACCCAGCTCTGAGGATTCC.
Determination of HCMV genome copy numbers. HFF-1 WT, control, or ZAP KO cells were infected
with HCMV WT at an MOI of 0.1 for 2 h at 37°C. After this time, cells were washed once with fresh me-
dium and incubated at 37°C. At the indicated time points, cells were scraped into the supernatants, and
cells and supernatant were harvested together. DNA from 200ml of the samples was extracted using the
Qiagen DNeasy blood and tissue kit (no. 69504) following the manufacturer’s protocol. Extracted DNA
was diluted 1:10 prior to qPCR for the analysis of HCMV genome copy numbers. HCMV DNA copy num-
bers were quantified with a real-time quantitative PCR as described previously (73). Copy numbers were
harmonized to the 1st WHO International Standard for Human Cytomegalovirus for Nucleic Acid
Amplification Techniques (NIBSC, no. 09/162).
Total proteome analyses using LC-MS/MS. HFF-1 WT or ZAP KO (250,000 cells/well in a 6-well for-
mat) were mock-treated or infected with HCMV WT at an MOI of 0.1, and the infection was enhanced by
centrifugation at 684 g at 30°C for 45min. The moment when the virus was added to the cells was
defined as time point 0. After centrifugation, cells were incubated at 37°C for 30 min followed by re-
moval of the virus-containing medium, one wash with DMEM, and replacement with fresh medium. At
the indicated time points, cells were washed with PBS once and then collected in 300ml of fresh PBS per
well. Cell pellets were frozen at 270°C. Two wells were combined to obtain a total of 500,000 cells per
condition. Quadruplicates of HCMV-infected HFF-1 cells were analyzed at 48 and 72h postinfection. For
each replicate, cells were washed with PBS, lysed in SDS lysis buffer (4% SDS, 10mM dithiothreitol [DTT],
50mM Tris/HCl pH 7.6), boiled at 95°C for 5min, and sonicated (4°C, 10min, 30 sec on, 30 sec off;
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Bioruptor). Protein concentrations of cleared lysates were normalized, and cysteines were alkylated with
5.5mM indole-3-acetic acid (IAA) (20min, 25°C, in the dark). SDS was removed by protein precipitation
with 80% (vol/vol) acetone (220°C, overnight), and protein pellets were washed with 80% (vol/vol) ace-
tone and resuspended in 40ml U/T buffer (6M urea, 2M thiourea in 10mM HEPES, pH 8.0). Protein diges-
tion was performed by subsequent addition of 1mg LysC (3 h, 25°C) and 1mg trypsin in 160ml digestion
buffer (50mM ammonium bicarbonate, pH 8.0) at 25°C overnight. Peptides were desalted and concen-
trated using C18 stage tips as described previously (74). Purified peptides were loaded onto a 50-cm
reverse-phase analytical column (75mm diameter; ReproSil-Pur C18-AQ 1.9mm resin; Dr. Maisch) and
separated using an EASY-nLC 1200 system (Thermo Fisher Scientific). A binary buffer system consisting
of buffer A (0.1% formic acid in H2O) and buffer B (80% acetonitrile, 0.1% formic acid in H2O) with a 120-
min gradient (5 to 30% buffer B [95min], 30 to 95% buffer B [10min], wash out at 95% buffer B [5min],
decreased to 5% buffer B [5min], and 5% buffer B [5min]) was used at a flow rate of 300 nl per min.
Eluting peptides were directly analyzed on a Q-Exactive HF mass spectrometer (Thermo Fisher
Scientific). Data-dependent acquisition included repeating cycles of one MS1 full scan (300 to 1,650m/z,
R= 60,000 at 200m/z) at an ion target of 3 106, followed by 15 MS2 scans of the highest abundant iso-
lated and higher-energy collisional dissociation (HCD) fragmented peptide precursors (R=15,000 at
200m/z). For MS2 scans, collection of isolated peptide precursors was limited by an ion target of 1 105
and a maximum injection time of 25ms. Isolation and fragmentation of the same peptide precursor
were eliminated by dynamic exclusion for 20 s. The isolation window of the quadrupole was set to
1.4m/z, and HCD was set to a normalized collision energy of 27%. Raw files were processed with
MaxQuant (version 1.6.14.0) using the standard settings and label-free quantification (LFQ) and match
between runs options enabled. Spectra were searched against forward and reverse sequences of the
reviewed human proteome, including isoforms (UniProtKB, release 01.2019) and of the HCMV proteins
(accession number GenBank accession no. EF999921.1) by the built-in Andromeda search engine (75).
The output of MaxQuant was analyzed with Perseus (version 1.6.14.0) (76), R (version 3.6.0), RStudio
(version 1.2.1335), and GraphPad Prism (version 7.04). Detected protein groups identified as known con-
taminants, reverse sequence matches, only identified by site, or quantified in less than 3 out of 4 repli-
cates in at least one condition were excluded. Following log2 transformation, missing values were input
for each replicate individually by sampling values from a normal distribution calculated from the original
data distribution (width = 0.3 · S.D., downshift = 21.8 · S.D.). Differentially expressed protein groups
between biological conditions were identified via two-sided Student’s t tests corrected for multiple
hypotheses testing applying a permutation-based false-discovery rate (FDR) (250 randomizations).
Total transcriptome analyses (RNA sequencing). HFF-1 WT, control, and two independent ZAP KO
cells (250,000 cells/well in a 6-well-plate format) were untreated, mock-treated, or infected by centrifugal
enhancement at 684 g and 30°C for 45 min with HCMV WT at an MOI of 0.1. The moment when the vi-
rus was added to the cells was defined as time point 0. After centrifugation, cells were incubated at 37°C
for 30 min followed by removal of the virus-containing medium and washed with fresh DMEM once.
Medium was then replaced with previously conditioned medium (medium in which the cells were origi-
nally seeded was kept at 37°C during the infection time). Cells were lysed at the indicated time points
using TRIzol for 2 min at room temperature and kept at 270°C. Two wells were combined to obtain
around 500,000 cells per sample. Total RNA was isolated using the RNA clean and concentrator kit
(Zymo Research) according to the manufacturer’s instructions. Sequencing libraries were prepared using
the NEBNext Ultra II directional RNA library prep kit for Illumina (NEB; catalog no. E7760) following polyA
RNA enrichment (NEB; catalog no. E7490) with 9 cycles of PCR amplification and sequenced on a HiSeq
4000 1 50-cycle flow cell.
Alignments were done using HISAT 2 (77). Sequencing reads were aligned to the hg19 version of the
human genome using standard parameters, using the Refseq gtf file downloaded from the UCSC ge-
nome browser. Reads were then quantified using QuasR (78) and the above-mentioned gtf file or the
HCMV TB40/E annotation (GenBank accession number MF871618). Differential expression and corre-
sponding P values were calculated using edgeR (79). Plots were created using ggplot2 (80) and pheat-
map (version 1.0.12) (https://cran.r-project.org/web/packages/pheatmap/index.html).
SLAM sequencing. HFF-1 WT or ZAP KO (g3) cells (250,000 cells/well in a 6-well format) were left
untreated or infected with HCMV WT at an MOI of 0.1, and the infection was enhanced by centrifugation
at 684 g at 30°C for 45min. The moment when the virus was added to the cells was defined as time
point 0. After centrifugation, cells were incubated at 37°C for 30 min followed by removal of the virus-
containing medium, one wash with DMEM, and replacement with fresh medium. Newly synthesized
RNA was labeled with 4-thiouridine (4sU) for 1 h prior to cell lysis. Cells were lysed at the indicated time
points using TRIzol for 5 min at room temperature and kept at 270°C. Two wells were combined to
obtain around 500,000 cells per sample. Total RNA was isolated using the DirectZOL kit (Zymo Research)
according to the manufacturer’s instructions, including the optional on-column DNase digestion. The
4sU alkylation reaction was essentially performed as published before (39). Briefly, 7.5 to 15mg total
RNA was incubated in 1 PBS (pH 8) containing 50% dimethyl sulfoxide (DMSO) and 10mM IAA at 50°C
for 15 min. The reaction was quenched with 100mM DTT, and RNA was purified using the RNeasy kit
(Qiagen). The quality and integrity of the total RNA were controlled on a 5200 fragment analyzer system.
The RNA sequencing library was generated from 100 ng total RNA using a NEBNext single cell/low input
RNA library according to the manufacture’s protocols. The libraries were sequenced on an Illumina
NovaSeq 6000 device using a NovaSeq 6000 S1 reagent kit (300 cycles, paired-end run, 2 150 bp) with
an average of 40 106 reads per RNA sample.
SLAM-seq was performed in duplicates to identify newly synthesized and total RNA using
GRAND-SLAM. Sequencing adapters (AGATCGGAAGAGCACACGTCTGAACTCCAGTCA, AGATCGGAAG
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AGCGTCGTGTAGGGAAAGAGTGT) were trimmed using Trimmomatic (version 0.39) (81). Reads were mapped
to a combined index of the human genome (Hg38/Ensembl version 90) and the HCMV genome (GenBank
accession number EF999921.1) using STAR (version 2.5.3a) with the parameters –outFilterMismatchNmax
20 –outFilterScoreMinOverLread 0.3 –outFilterMatchNminOverLread 0.3 –alignEndsType Extend5pOfReads12
–outSAMattributes nM MD NH. We used GRAND-SLAM (version 2.0.5d) (40) to estimate the new-to-total RNA
ratios. We only used the parts of the reads that were sequenced by both mates in a read pair (parameter
-double) for the estimation. New RNA was computed by multiplying total RNA with the maximum a posteri-
ori estimate of the new-to-total RNA ratio. For further analyses, we removed all cellular genes that had less
than 1 transcript per million transcripts (TPM) in more than 6 (cellular genes) or 2 (viral genes) samples. To
remove artifacts due to imprecise quantification, we furthermore removed all viral genes with less than 100
new reads. Log2 fold changes were estimated using PsiLFC (82) with uninformative prior (corresponding to
no pseudocounts). Normalization factors were computed from total RNA such that the median log2 fold
change was 0 and applied to both total and new RNA.
Enhanced cross-linking and immunoprecipitation (eCLIP) sequencing. HFF-1 WT cells (50 106
cells) were infected with HCMV WT at an MOI of 1 for 3 h at 37°C and 7.5% CO2. After this time, cells
were washed once with fresh DMEM and replace with fresh medium. At 20 hpi, the cells were UV cross-
linked using a BLX-254 VILBER cross-linker equipped with 254-nm light bulbs. Briefly, the culture me-
dium was removed, and cells were washed once with ice-cold PBS followed by cross-linking on ice.
Cross-linking was performed at 254 nm and 0.8 J/cm2 UV light. Cells were collected by scraping using
ice-cold PBS, followed by centrifugation at 400 g at 4°C for 5min. The cell pellet was washed once
with ice-cold PBS and frozen down in liquid nitrogen. Frozen cell pellets were lysed in 50mM Tris-HCl
pH 7.4, 150 mM NaCl, 1mM EDTA, 1% (vol/vol) NP-40, 0.5% NaDeoxycholate, 0.25mM TCEP [Tris(2-car-
boxyethyl)phosphine hydrochloride], and complete EDTA-free protease inhibitor cocktail. Subsequent
steps were performed as described in the eCLIP protocol (42), with the following modifications.
Immunoprecipitates were washed two times in 1ml CLIP lysis buffer and two times in IP wash buffer
(50mM Tris-HCl pH 7.4, 300mM NaCl, 1mM EDTA, 1% [vol/vol] NP-40, 0.5% sodium deoxycholate,
0.25mM TCEP), followed by two washes in 50mM Tris-HCl pH 7.4, 1mM EDTA, and 0.5% (vol/vol) NP-40.
All other steps were carried out as described in the eCLIP method. Briefly, following cell lysis, unpro-
tected RNA was digested, and ZAP was immunoprecipitated using a specific antibody. Cross-linked pro-
tein-RNA complexes were separated by SDS-PAGE, followed by nitrocellulose transfer. Bands migrating
at the expected size range were excised, and recovered RNA fragments were converted into a cDNA
library according to the eCLIP procedure (42). Sequencing was performed using the NextSeq 500 tech-
nology. For immunoprecipitation reactions, a specific antibody against ZAP (ZC3HAV1) (Proteintech,
16820-1-AP) was used.
Paired-end sequencing reads from eCLIP experiments were trimmed using a custom Python script
that simultaneously identified the umi-molecular identifier (UMI) associated with each read. Trimmed
reads were then aligned to the HCMV genome (GenBank accession number EF999921.1) and the human
genome (Hg38/Ensembl v100) using the Burrows-Wheeler Aligner (83) (version 0.7.15-r1140). Next, we
removed PCR duplicates using the UMI-aware deduplication functionality in Picard’s MarkDuplicates,
and the generated .bam files were then split by strand using “samtools view -f/-F 16” and converted to .bw
(bigwig format) using bamCoverage (84). Finally, ZAP binding sites were identified as peaks that were
enriched relative to a size-matched input control. MACS2 (85) (version 2.2.7.1) callpeak was used with the pa-
rameters -f BAM –keep-dup all –nomodel –extsize 50 –d-min 5 –scale-to small -B.
For comparing the binding site with gene expression (Fig. 6D and Fig. S6), all binding sites overlap-
ping the annotated region of the gene were identified using custom scripts, and the binding site with
the strongest enrichment was used. For the binding preference analysis, the set of strongly expressed
genes defined by our SLAM-seq data was used (see SLAM sequencing section). For each of these genes,
the sequences of the transcript isoform that had the most peaks (and the longest in case more than one
transcript had the same number of peaks) were extracted. Within each of these transcripts, dinucleotide
counts inside and outside the whole binding site regions defined by MACS2 were identified with a cus-
tom script for Fig. 6B. Furthermore, the position directly upstream of the 59 end of the second read of an
eCLIP read pair was considered to be the site of cross-linking. Sequences 6100 nucleotides (nt) of the
main cross-linking site (defined as the position in a transcript isoform having the maximal number of
cross-linking events) were extracted from the transcript sequences (excluding introns), and dinucleotides
were counted for each position using custom scripts for Fig. 6C. DREME (version 5.0.1) (43) was used to
identify sequence motifs (with the parameter -norc) in these sequences.
Statistical analyses. For qRT-PCR and genome copy number quantification, differences between
data sets were evaluated after log transformation with Student’s t-test (unpaired, two-tailed), using
GraphPad Prism version 5.0 (GraphPad Software, San Diego, CA). P values of, 0.05 were considered stat-
istically significant.
Data availability. The mass spectrometry proteomics data have been deposited in the ProteomeXchange
Consortium via the PRIDE (86) partner repository with the data set identifier PXD023559.
The raw sequencing data, including SLAM-seq, RNA-seq, and CLIP-seq, have been deposited in the
NCBI GEO database, with the accession number GSE159853.
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